Novain (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride, the active ingredient in Novain, is a local anesthetic presented as a sterile ophthalmic solution for ocular use. It provides temporary surface anesthesia for diagnostic eye examinations and minor ophthalmic procedures in adult patients. The drug acts rapidly, typically within seconds, and the effect lasts for several minutes, allowing clinicians to perform precise assessments without discomfort.

GNH USA supplies Novain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions.

Novain, an ophthalmic local anesthetic, is used to achieve temporary numbness of the ocular surface for procedures involving the eye.

Diagnostic ocular examinations: Provides temporary anesthesia to facilitate slit‑lamp biomicroscopy, fundus evaluation, and intraocular pressure measurement. Minor ophthalmic surgical procedures: Enables painless removal of corneal foreign bodies, minor laser treatments, and conjunctival biopsies. Contact lens fitting and removal: Reduces discomfort during lens manipulation and assessment.

Oxybuprocaine Hydrochloride may cause ocular and systemic reactions, most of which are mild and transient.

Common Side Effects: - Stinging or burning sensation upon instillation. - Transient blurred vision lasting a few minutes. - Conjunctival hyperemia (redness). - Mild tearing. - Temporary corneal epithelial irritation.

Serious or Rare Side Effects: - Corneal epithelial defect or ulceration with prolonged use. - Severe allergic reaction manifesting as eyelid edema, itching, and rash. - Anaphylaxis requiring emergency treatment. - Persistent visual impairment. - Secondary infection due to compromised corneal surface.

When using Novain, clinicians should observe several precautionary measures to minimize risks and ensure optimal outcomes.

Allergy assessment: Confirm no known hypersensitivity to oxybuprocaine or other ester‑type ocular anesthetics. Corneal integrity: Avoid use on damaged or ulcerated corneas unless benefits outweigh risks. Infection risk: Defer application in active bacterial or viral keratitis without appropriate antimicrobial coverage. Contact lens wear: Remove lenses before instillation and re‑insert only after anesthesia has resolved. Systemic exposure: Although minimal, avoid excessive dosing in patients with severe systemic disease. Store at room temperature: Keep in the original container, protect from light and moisture.

Oxybuprocaine can interact with other ophthalmic agents, influencing safety or efficacy.

Major Interactions (Avoid): - Concurrent use of multiple topical ocular anesthetics: Increases risk of cumulative corneal toxicity. - Combination with potent vasoconstrictors (e.g., phenylephrine) in the same eye: May exacerbate ocular irritation. - Use with preservative‑rich eye drops in compromised corneas: Heightens epithelial damage.

Moderate Interactions (Monitor Closely): - Co‑administration with topical antibiotics: May raise incidence of allergic conjunctivitis. - Simultaneous use of anti‑inflammatory eye drops (steroids or NSAIDs): Monitor for delayed wound healing. - Systemic medications that affect wound healing (e.g., corticosteroids): Observe ocular surface response.